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Abstract: Mammalian target of rapamycin (mTOR), a serine/threonine protein kinase and a master
regulator of cell growth and metabolism, forms two structurally and functionally distinct complexes,
mTOR complex 1 (mTORC1) and mTORC2. While mTORC1 signaling is well characterized,
mTORC2 is relatively poorly understood. mTORC2 appears to exist in functionally distinct pools,
but few mTORC2 effectors/substrates have been identified. Here, we review recent advances
in our understanding of mTORC2 signaling, with particular emphasis on factors that control
mTORC2 activity.
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1. Introduction
The target of rapamycin (TOR) was discovered in yeast nearly 30 years ago [1], and our
understanding of TOR signaling has since greatly expanded and keeps growing. Like yeast TOR,
mammalian TOR (mTOR, also known as mechanistic TOR [2]) is a central controller of cell growth and
metabolism [3,4]. mTOR signaling is physiologically important and its dysregulation is linked to many
diseases. It exists in the two structurally and functionally distinct complexes mTORC1 and mTORC2.
Compared to mTORC1, much is still unknown about mTORC2. mTORC2 was first described as a
rapamycin-insensitive complex that regulates organization of the actin cytoskeleton [5,6], as previously
shown for yeast TORC2 [7,8]. Here we review the structure, effectors, localization, and regulation of
mTORC2, and discuss future perspectives.
2. mTORC2 Composition and Structure
mTORC1 and mTORC2 share two essential core subunits, the kinase catalytic subunit mTOR
and mammalian lethal with SEC13 protein 8 (mLST8). The specific core subunit of mTORC1 is
regulatory-associated protein of mTOR (RAPTOR), whereas rapamycin-insensitive companion of
mTOR (RICTOR) and mammalian stress-activated Map kinase-interacting 1 (mSIN1) are unique core
subunits of mTORC2 (Figure 1). RICTOR mainly has a scaffolding role, and mSIN1 likely contains the
substrate binding site and determines subcellular localization of mTORC2. All four core subunits of
mTORC2 are essential for mTORC2 activity, but knockout of mLST8 appears not to affect mTORC1
activity [9]. mLST8 loss weakens mTOR interaction with RICTOR and mSIN1 in mTORC2, but not
with RAPTOR in mTORC1 [9–11]. K63-type polyubiquitination of mLST8 at K305 and K313 prevents
mTORC2 assembly and signaling [10]. The mTORC2 structure suggests that mLST8 might help mSIN1
in substrate recruitment and mLST8 ubiquitination could potentially disrupt this [12].
DEP-domain-containing mTOR-interacting protein (DEPTOR) is a regulatory component of both
mTORC1 and mTORC2. DEPTOR inhibits mTORC1 and mTORC2, likely via binding of its PDZ
domain to mTOR [13]. Proteins associated with RICTOR 1 (PROTOR1) and 2 (PROTOR2) are additional
components of mTORC2 [14–16], but do not seem to affect intrinsic mTORC2 activity [17]. The Tti1-Tel2
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complex, which interacts with mTOR directly, is required for stability of mTOR and assembly of both
mTORC1 and mTORC2 [18,19].Genes 2020, 11, x FOR PEER REVIEW 2 of 19 
 
 
Figure 1. Composition of mTORC2 core. mTORC2 is composed of four core subunits (mTOR, 
RICTOR, mSIN1, and mLST8). mTOR is composed of several domains, including the HEAT 
(huntingtin, elongation factor 3, a subunit of protein phosphatase 2A, TOR1; a tandemly repeated 
motif with helical structure), FAT (FRAP, ATM, TRRAP; α helices arranged as repeats), FRB 
(FKBP12–rapamycin binding), kinase, and FATC (FRAP, ATM, TRRAP, C-terminal; an α-helix and a 
disulfide-bonded loop) domains. RICTOR has armadillo (ARM; two curved layers of α-helix) 
repeats, a HEAT-like domain (HD), and a C-terminal domain (CD), and all three regions likely 
interact with mSIN1. A flexible region between HD and CD contains most of the identified RICTOR 
phosphorylation sites. mSIN1 is composed of NTD (N-terminal domain), CRIM (conserved region in 
the middle; substrate recruitment), RBD (Ras binding domain), and PH (pleckstrin homology; has 
membrane targeting capacity) domains. NTD and CRIM regions of mSIN1 have direct contact with 
RICTOR and mLST8. mLST8 is composed mainly of WD40 repeats and interacts with the kinase 
domain of mTOR. 
DEP-domain-containing mTOR-interacting protein (DEPTOR) is a regulatory component of 
both mTORC1 and mTORC2. DEPTOR inhibits mTORC1 and mTORC2, likely via binding of its 
PDZ domain to mTOR [13]. Proteins associated with RICTOR 1 (PROTOR1) and 2 (PROTOR2) are 
additional components of mTORC2 [14–16], but do not seem to affect intrinsic mTORC2 activity [17]. 
The Tti1-Tel2 complex, which interacts with mTOR directly, is required for stability of mTOR and 
assembly of both mTORC1 and mTORC2 [18,19]. 
The structure of the mTORC2 core has been resolved at intermediate resolution by two 
independent groups [20,21]. Recently, the 3.2 Å resolution structure of mTORC2 core was defined, 
with significantly improved building of RICTOR and mSIN1 regions [12]. mTORC2 is a homodimer 
of mTOR, mLST8, RICTOR, and mSIN1 heterotetramers. mTOR-mLST8 in mTORC2 adopts a 
similar conformation as in mTORC1. RICTOR interacts and forms multiple contacts with mTOR. 
The C-terminal domain of RICTOR masks the FKBP-rapamycin binding domain in mTOR, thus 
explaining the rapamycin insensitivity of mTORC2. RICTOR has an ATP-binding site, but its role is 
uncharacterized. The N terminus of mSIN1 is an integral component of mTORC2 that connects 
RICTOR to mLST8. The middle and C-terminal parts of mSIN1, as well as a region of RICTOR (aa 
1008–1559) that is predicted to be disordered, remain to be resolved due to high flexibility. 
3. mTORC2 Effectors 
Although many mTORC1 substrates have been identified, mTORC2 is known to phosphorylate 
mainly AGC kinases [22], including Akt (also known as protein kinase B, PKB), protein kinase C 
(PKC) family members, and serum- and glucocorticoid-induced kinases 1 (SGK1) at their 
hydrophobic motif (HM) and turn motif (TM). 
3.1. AGC Kinase HM 
The best characterized kinase activity of mTORC2 is its phosphorylation of Ser473 in the HM of 
Akt [23,24]. The functional output of Ser473 phosphorylation is context-dependent. For example, in 
mSIN1 knockout mouse embryonic fibroblasts (MEFs), Akt cannot phosphorylate forkhead box 
O1/3a (FoxO1/3a), but it can phosphorylate other substrates such as tuberous sclerosis complex 2 
(TSC2) and glycogen synthase kinase 3 (GSK-3) [25]. Liver-specific RICTOR knockout disrupts 
insulin-Akt signaling to FoxO1 and GSK3α/β [26], whereas the phosphorylation of multiple Akt 
substrates, including FoxO1, GSK3β, AS160, and PRAS40, is not affected by adipose-specific 
Figure 1. Composition of mTORC2 core. mTORC2 is composed of four core subunits (mTOR, RICTOR,
mSIN1, and mLST8). mTOR is composed of several domains, including the HEAT (huntingtin,
elongation factor 3, a subunit of protein phosphatase 2A, TOR1; a tandemly repeated motif with helical
structure), FAT (FRAP, ATM, TRRAP; α helices arranged as repeats), FRB (FKBP12–rapamycin binding),
kinase, and FATC (FRAP, ATM, TRRAP, C-terminal; an α-helix and a disulfide-bonded loop) domains.
RICTOR has armadillo (ARM; two curved layers of α-helix) repeats, a HEAT-like domain (HD), and a
C-terminal domain (CD), and all three regions likely interact with mSIN1. A flexible region between
HD and CD contains most of the identified RICTOR phosphorylation sites. mSIN1 is composed of
NTD (N-terminal domain), CRIM (conserved region in the middle; substrate recruitment), RBD (Ras
binding domain), and PH (pleckstrin homology; has membrane targeting capacity) domains. NTD and
CRIM regions of mSIN1 have direct contact with RICTOR and mLST8. mLST8 is composed mainly of
WD40 repeats and interacts with the kinase domain of mTOR.
The structure of the mTORC2 core has been resolved at intermediate resolution by two independent
groups [20,21]. Recently, the 3.2 Å resolution structure of mTORC2 core was defined, with significantly
improved building of RICTOR and mSIN1 regions [12]. mTORC2 is a homodimer of mTOR, mLST8,
RICTOR, and mSIN1 heterotetramers. mTOR-mLST8 in mTORC2 adopts a similar conformation as
in mTORC1. RICTOR interacts and forms multiple contacts with mTOR. The C-terminal domain
of RICTOR masks the FKBP-rapamycin binding domain in mTOR, thus explaining the rapamycin
insensitivity of mTORC2. RICTOR has an ATP-binding site, but its role is uncharacterized. The N
terminus of mSIN1 is an integral component of mTORC2 that connects RICTOR to mLST8. The middle
and C-terminal parts of mSIN1, as well as a region of RICTOR (aa 1008–1559) that is predicted to be
disordered, remain to be resolved due to high flexibility.
3. C2 Effectors
Although many mTORC1 substrates have been identified, mTORC2 is known to phosphorylate
mainly AGC kinases [22], including Akt (also known as protein kinase B, PKB), protein kinase C (PKC)
family members, and serum- and glucocorticoid-induced kinases 1 (SGK1) at their hydrophobic motif
(HM) and turn motif (TM).
3.1. AGC Kinase HM
The best characterized kinase activity of mTORC2 is its phosphorylation of Ser473 in the HM
of Akt [23,24]. The functional output of Ser473 phosphorylation is context-dependent. For example,
in mSIN1 knockout mouse embryonic fibroblasts (MEFs), Akt cannot phosphorylate forkhead box
O1/3a (FoxO1/3a), but it can phosphorylate other substrates such as tuberous sclerosis complex
2 (TSC2) and glycogen synthase kinase 3 (GSK-3) [25]. Liver-specific RICTOR knockout disrupts
insulin-Akt signaling to FoxO1 and GSK3α/β [26], whereas the phosphorylation of multiple Akt
substrates, including FoxO1, GSK3β, AS160, and PRAS40, is not affected by adipose-specific RICTOR
knockout [27]. mTOR kinase inhibitors PP242 and Torin1 were able to reduce the phosphorylation of
PRAS40 but not GSK3β in rat adipocytes [28]. Inhibition of mTORC2 has no effect on phosphorylati n
of GSK3β at Ser9 in ma y c n exts because GSK3β can be phosph ryla e by kinases th r than Akt,
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such as S6K, PKC, and Aurora A [29–31]. Chronic disruption of mTORC2 may cause compensatory
changes, and specificity of chemical inhibitors is also a concern. Nevertheless, these findings suggest
that mTORC2 phosphorylation of Ser473 is required for context dependent Akt activity toward some,
but not all, substrates. Indeed, the direct contribution of Ser473 phosphorylation to Akt activity was
recently assessed. It has been proposed that Ser473 phosphorylation activates Akt by disrupting
an autoinhibition conformation [32]. A recent study in adipocytes showed that mutation of Akt2
Ser474 (homologous to Ser473 in Akt1) reduced Akt2 activity by about 50% against its substrates TSC2,
PRAS40, FoxO1/3a, and AS160 [33]. This suggests a role of Ser473 phosphorylation in promoting
maximal Akt activity, rather than determining substrate specificity. Diffusion measurements in live
cells showed that phosphorylated, active Akt is restricted mainly to cellular membranes [34]. The exact
effects of mTORC2 on endogenous Akt toward its substrates in different contexts inside cells need
further study.
Besides Akt, mTORC2 also phosphorylates the HM of PKCs and SGK1. The PKC family can be
divided into three groups: the conventional c-PKCs (α, β and γ), the novel n-PKCs (δ, ε, η, θ, and µ),
and the atypical a-PKCs (ι and ζ). mTORC2 selectively mediates phosphorylation of the HM of c- and
n-PKCs, including types α, β, γ, and ε [35,36]. PKCαHM phosphorylation by mTORC2 regulates actin
polymerization [5,6]. In addition, mTORC2 phosphorylates the HM in SGK1 and thereby activates
SGK1 [37,38].
3.2. AGC Kinase TM
mTORC2 associates with the ribosome to phosphorylate nascent Akt at its TM (Thr450) during
translation [39]. This phosphorylation event prevents premature Akt ubiquitination and increases the
stability of nascent Akt polypeptide. As is the case with the HM, TM phosphorylation of c-PKCs (α, β,
and γ) and n-PKC (ε) is mediated by mTORC2 [35,36]. mTORC2 also phosphorylates the TM of an
atypical PKC, type ζ [40]. TM phosphorylation of PKCα is required for its maturation and stability.
Whether mTORC2 phosphorylates the TM in SGK1 is not clear.
3.3. Other mTORC2 Effectors
Only a limited number of mTORC2 substrates have been identified. Besides classical HM and
TM sites, mTORC2 also phosphorylates Ser477 and Thr479 at the C terminus of Akt under growth
stimulation conditions. These two sites are proposed to be essential for Akt activity, and can be
alternatively phosphorylated by Cdk2/Cyclin A during cell cycle progression [41,42]. The ubiquitin
ligase subunit F-box and WD repeat domain-containing 8 (FBW8) mediates the degradation of insulin
receptor substrate-1 (IRS-1), and mTORC2 stabilizes FBW8 by phosphorylating it at Ser86. mTORC2
thus negatively feeds back to IRS-1 to diminish insulin signaling [43]. mTORC2 promotes insulin-like
growth factor 2 (IGF2) production by co-translationally phosphorylating IGF2 mRNA-binding protein
1 (IMP1) at Ser181 [44]. Although mTORC2 has been proposed to have tyrosine kinase activity against
insulin receptor (InsR) and insulin-like growth factor 1 receptor (IGF1R), the involved mechanisms
need to be further clarified [45].
Like mTORC1, mTORC2 is also a central hub for cell metabolism involving amino acids, glucose,
nucleotides, fatty acids, and lipids [46–48]. The cysteine–glutamate antiporter xCT, also known as
solute carrier family 7 member 11 (SLC7A11), is a 12-pass transmembrane protein that takes up
cysteine in exchange for glutamate. mTORC2 can inhibit the activity of xCT via phosphorylation of
xCT Ser26 [49]. Defining mTORC2 effectors has relied largely on genetic studies, and many roles of
mTORC2 in metabolism are likely attributable to indirect downstream effectors. For example, mTORC2
promotes ATP-citrate lyase (ACLY) phosphorylation at Ser455, but this is likely mediated via Akt HM
phosphorylation. ACLY phosphorylation increases carbohydrate response element binding protein
(ChREBP) activity, histone acetylation, and gluco-lipogenic gene expression in brown adipocytes [50,51].
mTORC2 also regulates chemokine CXCL12-mediated angiogenesis via Akt HM phosphorylation [52].
Another mTORC2 effector, NDRG1 (N-Myc downstream regulated 1), is phosphorylated by the
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mTORC2 substrate SGK1 [37]. The cellular effect of this phosphorylation is unclear; however, NDRG1
is generally upregulated by stress signals, and could promote or suppress tumor formation under
certain conditions [53].
mTORC2 is required for other metabolic events. mTORC2 can regulate glycolysis and the pentose
phosphate pathway (PPP) via Akt and c-Myc. Akt phosphorylation by mTORC2 promotes glucose
uptake [54] and hexokinase 2 mediated glucose conversion to glucose-6-phosphate [55], the initial
steps of glycolysis. Glucose-6-phosphate can be alternatively used by PPP for ribose-5-phosphate and
nicotinamide adenine dinucleotide phosphate (NADPH) production. mTORC2 upregulates c-myc
through FoxO acetylation, and controls the expression of multiple enzymes in glycolysis and PPP [56].
mTORC2 is required for acetylation of FoxOs, and this is likely mediated via Sirtuin6 suppression or
inhibitory phosphorylation of class IIa histone deacetylases [56,57].
As noted above, direct and indirect effectors of mTORC2 contribute to complex cellular functions,
involving growth factor signaling and cell metabolism. Although mTORC2 plays important roles in
physiology and in pathophysiology such as metabolic diseases and cancer [58–61], in many cases we
still await a complete understanding of the underlying direct molecular links.
4. Subcellular Localization of mTORC2
Distinct pools of mTORC2 at different subcellular locations could underlie mTORC2 signaling
through different effectors [62]. Accumulating evidence supports the notion that mTORC2 localizes to
the cytoplasm, nucleus, plasma membrane, endosome, Golgi body, ribosome, lysosome, endoplasmic
reticulum (ER), mitochondria, and mitochondria-associated ER membrane (MAM) [63,64]. A so-called
LocaTOR2 reporter was recently developed to detect mTORC2 kinase activity toward Akt Ser473 at
different locations [65]. FRB-Akt2 is induced to be recruited by different FKBP-mCherry fusions to
six different membrane compartments, and the phosphorylation of FRB-Akt2 Ser473 is used as the
readout for the localized mTORC2. Using this reporter, mTORC2 was found to be active mainly at
the plasma membrane, mitochondria, and a subpopulation of endosomal vesicles. The observation
of mTORC2 activity in mitochondria supports the many reported phenotypic connections between
mTORC2 and mitochondria [66–68]. mTORC2 localizes to MAM upon stimulation by growth
factors [55]. Another report indicated that the association of mTORC2 with the ribosome is also growth
factor-dependent [69]. Since ribosomes exist at the ER, and MAM is a connection site for mitochondria
and ER, it is reasonable to hypothesize that the detected mitochondrial activity of mTORC2 could be
linked to its localization to MAM and ribosomes.
Different isoforms of mSIN1 have diverse locations and constitute at least three distinct mTORC2
pools [70,71]. At least two mSIN1 isoforms have the pleckstrin homology (PH) domain with
phosphoinositide-binding activity. Although there is controversy regarding which phosphoinositide
species bind to the PH domain, the PH domain is important for the localization of mSIN1, and thereby
mTORC2, to the plasma membrane [65,72,73]. The mSIN1 isoform, with a truncated C terminus, does
not have a PH domain but still forms a complex with other mTORC2 subunits. Not surprisingly,
this truncated isoform does not localize to the plasma membrane. Only mTORC2 with a PH domain
responds to insulin, so it is reasonable to suggest that the PH domain of mSIN1 determines the
localization of mTORC2 and is important for mTORC2 activation by insulin. Whether and how the
localization of mTORC2 to the plasma membrane is regulated in response to different cues remains to
be determined.
While mTORC2 activity toward other substrates/sites exists, the full spectrum of mTORC2
localization is likely underestimated using the LocaTOR2 reporter. Apart from the need to assess
mTORC2 activity at other subcellular locations, mTORC2 activity against certain substrates, such as
Akt TM phosphorylation, cannot be reflected by this reporter. Assembly of mTORC2 could be dynamic
and mTORC2 could potentially translocate from one site to another in response to different cues.
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5. TORC2 Regulation by Plasma Membrane Tension in Yeast
TORC2 is conserved in eukaryotes. The core subunits of TORC2 in the budding yeast Saccharomyces
cerevisiae are Tor2, Lst8, Avo3, and Avo1, with mTOR, mLST8, RICTOR, and mSIN1 as their mammalian
orthologues. Both mTORC2 and yeast TORC2 assemble into rhomboid-shaped dimers. Avo1 is 1176 aa,
whereas the longest isoform of its mammalian counterpart mSIN1 is only 522 aa. They both have
homologous PH domains that bind membranes, but mSIN1 has a much shorter N-terminal region that
connects with RICTOR and mLST8 in mTORC2. This might contribute to the functional differences
between mammalian and yeast TORC2.
Unlike mTORC2, which is found at many different subcellular locations, TORC2 in yeast
localizes mainly to specific regions of the plasma membrane, termed membrane compartments
containing TORC2 (MCTs) [74]. TORC2 activity is regulated by plasma membrane tension. Plasma
membrane stress, induced by either mechanical stretching or inhibition of lipid synthesis, leads
to redistribution of Slm proteins from invaginations called eisosomes to MCTs. Slm proteins then
promote TORC2-mediated Ypk1 phosphorylation, likely via recruitment of Ypk1 to the plasma
membrane [75,76]. Interestingly, decreased plasma membrane tension triggers phase separation
of phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) into invaginated membrane domains, which
cluster and inactivate TORC2 [77]. Together, these observations suggest that increased and decreased
membrane tension are sensed by mTORC2 via distinct mechanisms.
6. Regulation Cues for mTORC2 Activity
Compared with mTORC1, the regulation of mTORC2 activity is far less understood. Nevertheless,
it is clear that the phosphoinositide 3-kinase (PI3K) pathway mediates growth factor-induced Akt
Ser473 phosphorylation by mTORC2 (Figure 2). Recent evidence suggests that mTORC2 is also
activated by several other cues.
6.1. Growth Factor-Mediated Akt Phosphorylation at the Plasma Membrane
Numerous studies report that PI3K inhibition abolishes Akt phosphorylation at both Thr308
and Ser473, the latter of which is an mTORC2 target site. Mechanistically, upon growth factor
stimulation, PI3K phosphorylates PI(4,5)P2 at the plasma membrane to produce phosphatidylinositol
3,4,5-trisphosphate (PI(3,4,5)P3), which is counteracted by phosphatase and tension homolog (PTEN).
Akt and its activating kinase PDK1 specifically bind to PI(3,4,5)P3 via their PH domains, and are
recruited to the plasma membrane, leading to phosphorylation of Akt by PDK1 at Thr308. However,
the mechanism by which mTORC2 phosphorylates Akt Ser473 is controversial.
It has been proposed that PI(3,4,5)P3 directly activates mTORC2 [72]. As shown in model 1
(Figure 2A), the mSIN1 PH domain binds the mTOR kinase domain and auto-inhibits mTORC2.
PI(3,4,5)P3, but not the other PIPs, binds the mSIN1 PH domain and recruits mTORC2 to the
plasma membrane. In addition, the binding of PI(3,4,5)P3 to the mSIN1 PH domain releases the
inhibition of mTORC2 by mSIN1, in agreement with a previous study showing that PI(3,4,5)P3 directly
promotes mTORC2 activity in vitro [78]. With Akt Thr308 being phosphorylated by PDK1, the plasma
membrane-localized and activated mTORC2 further phosphorylates Akt at Ser473.
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conformation. In the box, S6K or Akt leads to dual phosphorylation of mSIN1 at Thr86 and Thr389 to 
inhibit mTORC2. In model 2 (B), mTORC2 permanently resides at the plasma membrane. 
Akt-pThr308 phosphorylates mSIN1 Thr86 within mTORC2, which in turn boosts mTORC2 activity. 
mTORC2 then phosphorylates Akt Ser473, leading to full activation of Akt. The contribution of 
mTORC2 containing Thr86-nonphosphorylated mSIN1 to Akt Ser473 phosphorylation is not very 
clear. 
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absence of growth factors, PDK1 and Akt are localized at the cytoplasm. Upon growth factor stimulation,
PI(4,5)P2 is converted to PI(3,4,5)P3 via PI3K at the plasma membrane, and PDK1 and Akt are recruited
to the plasma membrane via their pleckstrin homology (PH) domains, leading to phosphorylation of
Akt Thr308 by PDK1. In model 1 (A), PI(3,4,5)P3 recruits mTORC2 to the plasma membrane and directly
activates mTORC2 toward Akt Ser473 via the release of an inhibitory conformation. In the box, S6K or
Akt leads to dual phosphorylation of mSIN1 at Thr86 and Thr389 to inhibit mTORC2. In model 2 (B),
mTORC2 permanently resides at the plasma membrane. Akt-pThr308 phosphorylates mSIN1 Thr86
within mTORC2, which in turn boosts mTORC2 activity. mTORC2 then phosphorylates Akt Ser473,
leading to full activation of Akt. The contribution of mTORC2 containing Thr86-nonphosphorylated
mSIN1 to Akt Ser473 phosphorylation is not very clear.
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Two key ideas of the above model are as follows. First, the localization of mSIN1, and thereby
mTORC2, to the plasma membrane is PI(3,4,5)P3-dependent. Second, PI(3,4,5)P3 induces a structural
change in mTORC2 that increases its activity. However, a recent study using the LocaTOR2 reporter
challenged this model and suggested that mTORC2 permanently resides at the plasma membrane
and is constitutively active [65]. Unlike Akt, the localization of mSIN1 was shown not to change
with growth factor stimulation or PI3K inhibition. Slightly contrary to model 1, a previous study
showed that the mSIN1 PH domain binds many different PIPs, including PI(4,5)P2 and PI(3,4,5)P3 [73].
Once exogenous Akt2 is recruited to the plasma membrane, the LocaTOR2 reporter indicated that
mTORC2 activity is not affected by growth factors or PI3K. In agreement with this, myristoylated
Akt localizes to membranes and is constitutively active with phosphorylated Ser473 [79,80]. Thus,
translocation of Akt to the plasma membrane is both necessary and sufficient for its phosphorylation
by mTORC2.
Growth factor stimulated PI(3,4,5)P3 could indirectly promote mTORC2 activity. Phosphorylation
of mTOR Ser2481 might be involved, but its role is poorly characterized [81,82]. It was shown that
Akt phosphorylates mSIN1 Thr86 to activate mTORC2 in 3T3-L1 adipocytes [83]. The same group
later confirmed Akt as the major kinase for mSIN1 Thr86 phosphorylation in HeLa cells and in several
other contexts [84]. This positive feedback loop between Akt and mTORC2 supports another layer
of mTORC2 activation induced by growth factors. Combined with the LocaTOR2 study, model 2
is proposed (Figure 2B), in which Akt Ser473 phosphorylation is mediated by both translocation of
Akt to the plasma membrane and an increase of mTORC2 activity by Akt. However, whether mSIN1
Thr86 phosphorylation is a prerequisite for mTORC2 activity is not clear. If not, how much mTORC2
containing Thr86-nonphosphorylated mSIN1 contributes to total Akt Ser473 phosphorylation inside
cells is unknown.
The regulation of mTORC2 activity by mSIN1 phosphorylation is controversial. In another
study [85], the major kinase for mSIN1 Thr86 phosphorylation was confirmed to be Akt in 3T3-L1
adipocytes [83] and S6K in HeLa cells. This study also found that phosphorylation of another mSIN1
site, Thr389, requires both Akt and S6K in 3T3-L1, although it is mainly dependent on S6K in HeLa cells.
Phosphorylation of mSIN1 on both Thr86 and Thr398 further disassembles mTORC2 and suppresses
mTORC2 activity (Figure 2A), suggesting an mTORC1-to-mTORC2 negative feedback loop operating
via S6K. The discrepancies in the major kinase for mSIN1 phosphorylation and the effects of mSIN1
phosphorylation on mTORC2 activity need further study.
6.2. mTORC2 Activity Is Regulated by Its Subcelluar Localization
6.2.1. mTORC2 Is Active Mainly at Membrane Compartments
mTORC2 exists at multiple subcellular locations, but how mTORC2 subpopulations are
differentially regulated is poorly characterized (Figure 3). The LocaTOR2 reporter indicates that
mTORC2 is active mainly at the plasma membrane, outer mitochondrial membrane, and endosomal
vesicles [65]. mTORC2 activity cannot be detected in the cytoplasm or endoplasmic reticulum (ER),
and this is likely because either mTORC2 is not active or the counteracting phosphatases limit
mTORC2 activity at these locations. Sustained activation of the mTORC2 effector Akt requires binding
of PI(3,4,5)P3 or PI(3,4)P2 to the Akt PH domain, which protects membrane-localized Akt from
dephosphorylation [34]. mTORC2 at the plasma membrane is discussed in Section 6.1.
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Figure 3. Upstream of mTORC2 signaling. Besides canonical PI3K-mediated mTORC2 activation,
mTORC2 activity is controlled by its localization to different subcellular compartments, small GTPases,
nutrients, and metabolites.
6.2.2. Mitochondria, ER, and MAM
There are many lines of evidence linking mTORC2 to mitochondria and the ER (reviewed in [63]).
In addition, upon growth factor stimulation, mTORC2 localizes to MAM and phosphorylates Akt,
which in turn phosphorylates MAM-associated proteins, including the inositol 1,4,5-trisphosphate
receptor and hexokinase 2 [55]. MAM is a specialized region of the ER that abuts mitochondria, so the
mTORC2 subpopulation at MAM is associated with both mitochondria and the ER. However, these
three mTORC2 subpopulations seem to be different. mTORC2 at MAM is growth factor sensitive,
but the LocaTOR2 reporter indicates that mTORC2 is active at mitochondria but not ER, and that
mitochondria-localized mTORC2 is insensitive to PI3K and growth factors [65].
6.2.3. Ribosome
It was first noticed that mTORC2 associates with actively translating ribosomes [39] where
it phosphorylates the TM (Thr450) in nascent Akt. Another study showed that active mTORC2
is associated with the ribosome, and the ribosome is required for mTORC2 activation [69].
The mTORC2–ribosome association is induced by insulin-stimulated PI3K signaling and is independent
of protein synthesis. Although ribosome-bound mTORC2 might exist at MAM, the underlying
mechanism by which ribosome association activates mTORC2 is unknown.
6.2.4. Endosome and Lysosome
The LocaTOR2 reporter indicates that mTORC2 is active at early and late endosomes, but not at
recycling endosomes [65]. Indeed, i was found that the endosomal protein Appl1 is required for Ak
HM phosphorylation in zebrafish [86]. Nevertheless, it is unclear whether zebrafish TORC2 is directly
activated on endosomes in this context.
The discovery of the lysosome as a center for mTORC1 signaling has greatly improved our
understanding of how mTORC1 senses external nutrients and growth factors. Unexpectedly, it was
shown that perinuclear clustering of lysosomes delays reactivation not only of mTORC1, but also of
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mTORC2 and Akt upon serum replenishment [87]. Another study showed that lysosomal mTORC2
activates Akt to inhibit chaperone-mediated autophagy [88]. These findings further suggest that
different pools of mTORC2 exist and are regulated differently.
6.2.5. Nucleus
mTORC2 has been suggested to translocate between the nucleus and cytoplasm [89,90]. Inhibition
of c-PKC catalytic activity disrupts the localization of mSIN1 and SGK1 to the nucleus and perinuclear
compartment, and this further prevents SGK1 Ser422 phosphorylation by mTORC2 [62]. Although the
nuclear function of mTORC2 is still not clear, the subcellular distribution of mTORC2 to the nucleus
and perinuclear compartment may be relevant to its downstream effector SGK1.
6.3. GTPase Activation of mTORC2
Recent studies suggest the involvement of small GTPases in mTORC2 activation (Figure 3).
GTPases can activate mTORC2 indirectly via PI3K. Ras-GTP, but not Ras-GDP, interacts with PI3K
and increases its activity [91]. Rab35, another small GTPase, was identified in an shRNA screen as a
regulator of growth factor-stimulated PI3K signaling [92], which then activates mTORC2.
Direct roles of GTPases in mTORC2 activation have been recognized only recently. Rac1 is a
member of the Rho family of GTPases and binds directly to mTOR. In response to growth factor
stimulation, Rac1 was shown to regulate the activity of both mTORC1 and mTORC2, surprisingly,
independently of its binding to GTP or GDP [93]. Oncogenic Ras with impaired GTPase activity leads
to constitutively active Ras signaling. Ras-GTP directly binds mSIN1 and mTOR in mTORC2, which in
turn leads to mTORC2 activation at the plasma membrane [94]. The discovery of mTORC2 as a direct
Ras effector suggests a key module for tumorigenesis driven by Ras mutation. However, whether
direct mTORC2 activation by Ras-GTP is downstream of growth factors or PI3K is not clear. Another
member of the Ras family of GTPases, Rit, interacts with mSIN1 and mediates mTORC2 activation
following oxidative stress [95].
Interestingly, comparable and detailed roles of Ras-GTP in TORC2 activation in Dictyostelium were
found. The small GTPase Rap1 binds TORC2 component RIP3/SIN1 and regulates RasC-mediated
activation of TORC2 [96]. In another study, in response to G protein-coupled receptor activation
by chemoattractant, GDP-bound RacE is phosphorylated by GSK-3 and forms a super complex
with RasC-GTP and TORC2 to promote Akt phosphorylation [97]. Compared with Dictyostelium,
the contribution of Ras to TORC2 activation in mammals seems to be minor [94]. This is possibly due
to the complex subcellular distribution of mTORC2.
6.4. Nutrients and Metabolites
Although there is evidence showing that amino acids activate mTORC2 [98], it is widely accepted
that mTORC1 is sensitive to both nutrients and growth factors, whereas mTORC2 is mainly regulated
by growth factors. However, recent studies support a role of mTORC2 in metabolic reprograming and
show how mTORC2 responds to nutrients (Figure 3).
A decrease in glutamine catabolites due to nutrient deprivation can activate mTORC2 to increase the
expression of glutamine–fructose-6-phosphate amidotransferase 1 (GFAT1). mTORC2 thus modulates
a glutamine-requiring biosynthetic pathway to mediate metabolic homeostasis [99]. Acetyl coenzyme
A (Acetyl-CoA) is the acetyl group donor in protein acetylation, and RICTOR is acetylated at multiple
sites. p300-mediated acetylation of RICTOR increases mTORC2 activity, whereas deacetylases inhibit
RICTOR acetylation and mTORC2 activity [100]. Glucose and acetate can both replenish acetyl-CoA
and activate mTORC2 via RICTOR acetylation [101]. In contrast, glucose stress also activates mTORC2,
and its relevance to acetylation is unclear [102]. One possible explanation is that glucose starvation
activates 5′ adenosine monophosphate-activated protein kinase (AMPK), which increases mTORC2
activity (see below). Methyglyoxal, a metabolite produced mainly by glycolysis, and the metabolic
waste product ammonium both activate mTORC2, but the mechanisms are unclear [103,104]. It is
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worth mentioning that most of these metabolic inputs are in a stress-like state, so mTORC2 could
potentially mediate cell survival in starvation or even toxic conditions. The endogenous levels of these
metabolites in physiological or pathological conditions, and their contributions to mTORC2 activity in
specific contexts, should be investigated.
7. Signaling Crosstalk Regulates mTORC2 Activity
While most studies on mTORC2 investigate its regulation by PI3K, recent studies revealed that
mTORC2 activity is fine-tuned via other signaling pathways (Figure 4).
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7.1. Feedback Control between mTORC1 and mTORC2
Feedback control loops exist between mTORC1 and mTORC2 [105]. mTORC1 negatively regulates
mTORC2 via S6K1. S6K1, downstream of mTORC1, leads to inhibitory phosphorylation of IRS1
and also downregulation of IRS1 protein level [106–108]. Downregulation of insulin-PI3K signaling
then inactivates mTORC2. S6K1 can also phosphorylate RICTOR at Thr1135, but the functional
consequence of this phosphorylation is controversial, and it does not seem to affect mTORC2 kinase
activity [109–112]. S6K1 can phosphorylate mSIN1 at Thr86 and Thr389 to inhibit mTORC2 integrity,
but this is controversial (discussed in Section 6.1, Figure 2A).
mTORC1 regulates mTORC2 in another negative feedback loop via growth factor bound-receptor
protein 10 (Grb10) [113,114]. mTORC1 phosphorylates Grb10 at multiple sites and stabilizes the protein.
Grb10 inhibits phosphorylation of InsR and IRS-1/2, destabilizes IRS-1, and mediates the inhibition of
PI3K signaling and mTORC2 activity.
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7.2. AMPK Activates mTORC2
AMPK, a master regulator of cell energy homeostasis, is activated when there is a lack of energy or
nutrients [115]. AMPK downregulates mTORC1 in two ways. First, TSC2 phosphorylation by AMPK
likely increases the GTPase-activating protein (GAP) activity of the TSC complex toward the GTPase
Ras homolog enriched in brain (RHEB) and thereby inhibits mTORC1 [116]. Second, AMPK directly
phosphorylates RAPTOR to inactivate mTORC1 [117]. Given the negative feedback loops between
mTORC1 and mTORC2, AMPK-mediated mTORC1 inactivation may lead to mTORC2 activation
indirectly (see Section 7.1).
AMPK activates mTORC2 directly in response to energetic stress [118]. AMPK-activating
agonists promote mTORC2 signaling independently of mTORC1-mediated negative feedback. AMPK
phosphorylates mTOR and RICTOR, and this is sufficient to increase mTORC2 kinase activity.
The mechanisms by which this phosphorylation regulates mTORC2 activity, as well as the exact
phosphorylation sites, have yet to be fully defined. The direct input of AMPK to mTORC2 suggests a
new strategy for cell survival to cope with acute energetic stress.
7.3. Wnt Activates mTORC2
The canonical Wnt pathway leads to accumulation of β-catenin in the cytoplasm, followed by its
translocation into the nucleus to function as a transcription activator. The noncanonical planar cell
polarity (PCP) pathway, which involves Wnt but does not require β-catenin, results in reorganization
of the actin cytoskeleton [119]. Wnt3A activates mTORC2 to induce glycolysis during osteoblast
differentiation [120]. Low-density lipoprotein receptor-related protein 5 (LRP5), rather than the
canonical Wnt signaling component β-catenin, appears to be the principle mediator for this process.
Indeed, Wnt3A induces recruitment of Rac1 to the plasma membrane, and Wnt-LRP5 signaling
activates mTORC2 via Rac1. In skeletal muscle, Wnt7a binds directly to its receptor Frizzled-7 (Fzd7)
to activate the PCP pathway. The association of the Fzd7 receptor complex with PI3K likely leads to
the activation of PI3K, and mTORC2 as well [121]. Prickle-like protein 1 (Prickle1) is a PCP protein
phosphorylated by the misshapen-like kinase 1 (MINK1). Phosphorylated Prickle1 forms a complex
with mTORC2 through binding RICTOR, and further activates mTORC2 to regulate focal adhesion
and cancer cell migration [122].
7.4. Other Signaling Pathways
Other signaling pathways have also been shown to regulate mTORC2 indirectly or in a
context-dependent manner. YAP activates mTORC2. YAP is the main downstream target of the
mammalian Hippo pathway in the regulation of tissue growth [123]. It has been shown that YAP
directly induces the expression of miR-29 to inhibit translation of PTEN, which antagonizes PI3K [124].
YAP therefore enhances the production of PI(3,4,5)P3, which further activates mTORC2 and mTORC1.
Thus, YAP connects Hippo and mTOR signaling.
TGF-β activates mTORC2. TGF-β induces epithelial–mesenchymal transition (EMT),
a reprograming process widely existing in cancer, involved with cell shape and behavior changes.
In cells undergoing EMT, TGF-β induces mTORC2 activity and mTORC2 is required for EMT-associated
cell migration and invasion [125]. Pharmacological inhibition of mTOR or knockdown of RICTOR
dampens TGF-β-induced differentiation of human myofibroblasts, suggesting that mTORC2 acts
downstream of TGF-β signaling [126].
GSK-3 is a substrate of Akt and can regulate mTORC2 activity. Under ER stress, RICTOR
phosphorylation at Ser1235 by GSK-3 interferes with mTORC2 binding to its substrate Akt [127].
GSK-3 also directly phosphorylates RICTOR at another site, Thr1695. Phosphorylated RICTOR is
then recognized by the E3 ubiquitin ligase F-Box and WD repeat domain-containing 7 (FBW7) and is
degraded [128]. Although GSK-3 was reported to suppress mTORC2 activity in both studies, it has
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been reported to positively affect mTORC1 and mTORC2 in neurons [129]. Whether GSK-3 promotes
or inhibits TORC2 in Dictyostelium is also controversial [97,130–132].
8. Perspectives
Recent studies have indicated that mTORC2 has various subcellular locations, including distinct
membrane compartments, but the precise localization of mTORC2 is still elusive, and how different
pools of mTORC2 coordinate with each other is unclear. Whether and how sub-pools of mTORC2
sense and transduce distinct cues also remain largely unknown. mTORC2 activity is regulated by
diverse factors such as growth factors, metabolites, and signaling crosstalk. Molecular details of this
complex regulation process still need to be elucidated. Further studies are needed to obtain integrated
mechanisms and comprehensive understanding of mTORC2 activation. Finally, it is worth noting that
most mTORC2 studies have used Akt Ser473 phosphorylation as the readout of mTORC2 activity, due
to the availability of effective antibodies that recognize Akt pSer473. This greatly neglects the fact that
mTORC2 phosphorylates other effectors, possibly in response to other conditions [64].
Recent ‘omics’ studies have greatly advanced our understanding of mTOR signaling. Proteomics
and phosphoproteomics contributed to the identification of novel substrates, interactors, and functions.
Emerging evidence supports many undefined links of mTORC2 to membranes. Although analyzing
membrane proteins, especially plasma membrane proteins, is always challenging using a mass
spectrometry approach, optimized methods and new tools need to be developed [133]. Structural
resolution of mTORC2 with membranes, its substrates, or its upstream regulators will further improve
our understanding of mTORC2 signaling. Specific small molecules targeting mTORC2 still need
to be developed [134]. They will be useful not only to study mTORC2 signaling, but also have
therapeutic potential.
Hyperactive mTORC2 signaling is commonly found in cancer, and is tumorigenic in various
in vitro and in vivo models [135]. Several upstream regulators and downstream effectors of mTORC2
are well-known tumor suppressors or oncoproteins. Furthermore, RICTOR is overexpressed in
adenocarcinoma, glioma, sarcoma, and many other cancer types. RICTOR overexpression promotes
assembly of the mTORC2 complex, and its overexpression results from at least two mechanisms,
genomic amplification and miRNA regulation (reviewed in [136]). In the future, defining the regulation
of mTORC2 signaling may reveal novel drug targets [137].
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